HR+/HER2- EARLY BREAST CANCER
Clinical trials for HR+/HER2- EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tracking breast cancer treatment outcomes in real patients
Disease control Recruiting nowThis study follows 177 patients in Saudi Arabia who are already taking ribociclib plus hormone therapy for early-stage breast cancer. Researchers will observe how well the treatment works and what side effects occur in real-world medical practice over 3 years. The study doesn't c…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:13 UTC
-
New drug combo aims to shrink tumors before breast cancer surgery
Disease control Recruiting nowThis study is testing whether adding a drug called fluzoparib to standard chemotherapy is safe and effective at shrinking tumors before surgery. It is for people with a specific type of early-stage breast cancer (HR+/HER2- and HRD-positive). The goal is to see if this combination…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC